{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:40:08Z","timestamp":1776872408441,"version":"3.51.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clinthera.2024.11.011","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T23:46:26Z","timestamp":1733442386000},"page":"e1-e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Validation of Risk Models for Predicting Febrile Neutropenia Among Breast Cancer Patients Receiving Chemotherapy: A Real-World Study"],"prefix":"10.1016","volume":"47","author":[{"given":"Shu-Wei","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Chin","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4199-0867","authenticated-orcid":false,"given":"Yu","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.11.011_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0002","year":"2022","journal-title":"Cancer registry annual report, 2020"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0003","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0004","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"Jama"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","article-title":"Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice","volume":"6","author":"Crawford","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0006","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0007","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ajh.10363","article-title":"Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia","volume":"73","author":"Choi","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0008","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/CAD.0000000000000279","article-title":"Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy","volume":"26","author":"Hashiguchi","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0009","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/CEOR.S168298","article-title":"Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar","volume":"10","author":"Schwartzberg","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0010","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0011","series-title":"Hematopoietic growth factors, version 2. 2023","year":"2023"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0012","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0013","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0014","doi-asserted-by":"crossref","first-page":"pky053","DOI":"10.1093\/jncics\/pky053","article-title":"Development and validation of a risk score for febrile neutropenia after chemotherapy in patients with cancer: the FENCE score","volume":"2","author":"Aagaard","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.31557\/apjcb.2020.5.3.81-87","article-title":"Pretreatment absolute neutrophil-to-lymphocyte ratio (NLR) predict the risk for febrile neutropenia in the first cycle adjuvant chemotherapy for breast cancer","volume":"5","author":"Chantharakhit","year":"2020","journal-title":"Asian Pac J Cancer Biol"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0016","doi-asserted-by":"crossref","first-page":"e96413","DOI":"10.1371\/journal.pone.0096413","article-title":"Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0017","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/annonc\/mdn560","article-title":"Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer","volume":"20","author":"Jenkins","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0018","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdr493","article-title":"Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer","volume":"23","author":"Jenkins","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0019","volume":"10","author":"Thungthong","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10549-021-06155-1","article-title":"Variations in breast cancer surgical treatment and timing: determinants and disparities","volume":"188","author":"Dankwa-Mullan","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0021","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1007\/s00520-020-05295-2","article-title":"Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy","volume":"28","author":"Gawade","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0022","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/13696998.2016.1192548","article-title":"Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries","volume":"19","author":"Irwin","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0023","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.2337\/dc11-0699","article-title":"Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients","volume":"34","author":"Morden","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0024","doi-asserted-by":"crossref","first-page":"21698","DOI":"10.1038\/s41598-020-78569-8","article-title":"Trends and patterns in the use of opioids among metastatic breast cancer patients","volume":"10","author":"Shen","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0025","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1080\/03007995.2017.1386858","article-title":"Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015","volume":"33","author":"Weycker","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0026","series-title":"ICD-9-CM and ICD-10-CM codes for infectious disease","year":"2015"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0027","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/03007995.2019.1703665","article-title":"Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years","volume":"36","author":"Edelsberg","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0028","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1186\/s12913-022-08325-3","article-title":"Granulocyte colony stimulating factor use and adherence to clinical practice guidelines among women with breast cancer living in Puerto Rico: a population-based study","volume":"22","author":"Jim\u00e9nez Nieves","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0029","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkac038","article-title":"Validation of the FENCE risk groups for prediction of febrile neutropenia with first-cycle chemotherapy","volume":"6","author":"Zatarah","year":"2022","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0030","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2354.2009.01121.x","article-title":"Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours","volume":"19","author":"L\u00f3pez-Pousa","year":"2010","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0031","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00520-010-0821-1","article-title":"Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer","volume":"19","author":"Hosmer","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0032","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1002\/cam4.1580","article-title":"Value of incorporating newly identified risk factors into risk prediction for chemotherapy-induced febrile neutropenia","volume":"7","author":"Li","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.clinthera.2024.11.011_bib0033","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.6004\/jnccn.2017.7038","article-title":"A patient risk model of chemotherapy-induced febrile neutropenia: lessons learned from the ANC study group","volume":"15","author":"Lyman","year":"2017","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824003552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824003552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T14:48:01Z","timestamp":1738766881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824003552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0149291824003552"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.11.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of Risk Models for Predicting Febrile Neutropenia Among Breast Cancer Patients Receiving Chemotherapy: A Real-World Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}